Eli Lilly (LLY)
(Real Time Quote from BATS)
$884.22 USD
-6.85 (-0.77%)
Updated Oct 3, 2024 03:55 PM ET
After-Market: $885.35 +1.13 (0.13%) 4:18 PM ET
1-Strong Buy of 5 1
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$884.22 USD
-6.85 (-0.77%)
Updated Oct 3, 2024 03:55 PM ET
After-Market: $885.35 +1.13 (0.13%) 4:18 PM ET
1-Strong Buy of 5 1
D Value F Growth A Momentum F VGM
Zacks News
Pharma Stock Roundup: LLY Coronavirus Antibody Phase I Study Initiation, FDA Approvals
by Kinjel Shah
Lilly (LLY) begins phase I study on a potential COVID-19 antibody therapy. FDA grants label expansion approvals to several drugs.
Novartis (NVS) Announces Positive Data From Cosentyx Study
by Zacks Equity Research
Novartis (NVS) reports encouraging data from the phase III PREVENT study evaluating Cosentyx in patients with non-radiographic axial spondyloarthritis.
Roche's COVID-19 Test Gets FDA's Emergency Use Authorization
by Zacks Equity Research
Roche's (RHHBY) Elecsys IL-6 test gets FDA's EUA for identifying patients at high risk of severe inflammatory response.
Change Healthcare (CHNG) Q4 Earnings, Revenues Top Estimates
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal fourth-quarter results benefit from solid performance across the Network Solutions segment and higher revenues.
How Are Biotech ETFs Reacting to Coronavirus Treatment News?
by Sweta Jaiswal, FRM
Here we take a look at how the latest updates on drugs, antibody therapies and vaccines targeted at winning the coronavirus battle can affect biotech ETFs.
Bristol Myers' Zeposia Meet Goals in Ulcerative Colitis Study
by Zacks Equity Research
Bristol Myers' (BMY) late-stage study of Zeposia in patients with moderate-to-severe ulcerative colitis meets both its main goals.
HealthEquity (HQY) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
HealthEquity (HQY) witnessed strong growth in Service, Custodial and Interchange segments in Q1.
Lilly Begins Coronavirus Study to Evaluate Antibody Therapy
by Zacks Equity Research
Lilly (LLY) initiates dosing in a phase I study to evaluate an antibody candidate for treating COVID-19.
Coronavirus Treatment Search Still on, Lilly, Gilead Give Updates
by Kinjel Shah
Lilly (LLY) begins phase I study on a potential antibody therapy to treat COVID-19. Gilead (GILD) announces mixed results from the second phase III study on remdesivir in patients with moderate COVID-19.
NextGen (NXGN) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
NextGen's (NXGN) fiscal fourth-quarter 2020 results gain from strong Recurring revenues.
3 Strong Pharmaceutical and Biotech Stocks to Buy for Coronavirus Immunity
by Benjamin Rains
Let's dive into three large-cap pharmaceutical and biotech stocks that appear set to grow during the pandemic-induced downturn and the eventual recovery...
Top Stock Picks for Week of June 1, 2020
by Panel Of Zacks Experts
Two Zacks Strong Buy Stocks in Focus.
AbbVie Gets FDA Nod for Oriahnn to Control Menstrual Bleeding
by Zacks Equity Research
The FDA approves AbbVie's (ABBV) Oriahnn oral capsule for checking heavy menstrual bleeding related to uterine fibroids in pre-menopausal women. It will be sold in US markets by June-end.
Lilly's Cyramza Gets FDA Approval for First-Line Lung Cancer
by Zacks Equity Research
FDA approves Lilly's (LLY) Cyramza as a combination regimen for metastatic EGFR-mutated non-small cell lung cancer. Cyramza is now approved for six indications to treat four different types of cancers.
Pfizer's Ibrance Fails in Phase III Early Breast Cancer Study
by Zacks Equity Research
Pfizer's (PFE) phase III PALLAS study compared Ibrance plus standard adjuvant endocrine therapy to standard adjuvant endocrine therapy in HR+, HER2- early breast cancer.
Cooper Companies (COO) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Cooper Companies' (COO) fiscal second-quarter performance is likely to reflect better-than-expected performance at CVI and CSI.
FDA Okays Lilly's Alzheimer's Disease Diagnostic Agent Tauvid
by Zacks Equity Research
With the US regulatory agency's nod, Eli Lilly's (LLY) Tauvid became the first and the only approved radioactive diagnostic agent to image tau NFTs in the brain for effectively evaluating AD patients.
Pharma Stock Roundup: MRK, RHHBY Give Coronavirus Updates,SNY to Sell Stake in REGN
by Kinjel Shah
Merck (MRK), Glaxo (GSK) and Roche (RHHBY) make progress in coronavirus research efforts.
Veeva Systems (VEEV) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva Systems' (VEEV) core Subscription business segment performed impressively in Q1.
3 Investing Facts About Required Minimum Distributions You Need to Know - May 28, 2020
by Zacks Equity Research
Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.
Sanofi's Dupixent Gets FDA Approval for Eczema in Children
by Zacks.com
Sanofi (SNY) secures an FDA nod for Dupixent as the first biologic medicine for children aged from six to 11 years with moderate-to-severe atopic dermatitis.
Why Eli Lilly (LLY) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Eli Lilly (LLY) have what it takes? Let's find out.
Zacks.com featured highlights include: Eli Lilly and Company, Quidel, Everbridge and Sprouts Farmers Market
by Zacks Equity Research
Zacks.com featured highlights include: Eli Lilly and Company, Quidel, Everbridge and Sprouts Farmers Market
Top 4 Momentum Anomaly Stocks to Enhance Portfolio Returns
by Zacks Equity Research
These fast movers are currently witnessing a short-term pullback in price. So, this could be a solid entry point for garnering better returns.
Veeva Systems (VEEV) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Veeva Systems' (VEEV) fiscal first-quarter results are likely to reflect solid show by its segments and robust product portfolio.